cagrisema vs tirzepatide

cagrisema (B-tier) vs tirzepatide (S-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

cagrisema — tier B

semaglutide + cagrilintide. first fixed-dose GLP-1 + amylin combo. FDA review underway 2026.

semaglutide + cagrilintide. the first fixed-dose GLP-1 + amylin combo. NDA filed December 2025, expected FDA decision late 2026.

22.7% REDEFINE-1 phase 3 · half-life ~168 hours (once-weekly dosing, both components) · weight loss

tirzepatide — tier S

A dual GIP and GLP-1 receptor agonist with distinct Zepbound and Mounjaro labels.

The obesity record is strong, but every outcome must stay attached to its trial population and product label.

20.9% SURMOUNT-1 mean change at 15 mg · half-life ~5 days · weight loss

at a glance

• cagrisema: tier B · 22.7% REDEFINE-1 phase 3
• tirzepatide: tier S · 20.9% SURMOUNT-1 mean change at 15 mg

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.